Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

About this update from Kairos Pharma, Ltd.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: To our valued Kairos Pharma Shareholders, As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. We announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. The Company will be acquiring the worldwide rights for a highly differentiated, clinical-stage oncology asset targeting non-small cell lung cancer (NSCLC) and esophageal and gastric cancer: CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. CL-741 is a Phase 1-ready therapeutic candidate targeting EGFR-mutated lung cancer, a treatment landscape valued at an estimated $16.2B in 2026 (Future Market Insights). We intend to utilize Kairos’s proven expertise in developing drug-resistance therapeutics and establishing strong clinical partnerships to accelerate CL-741's pathway for patients with EGFR-mutant and c-MET-driven lung cancers. CL-741 will add to our already existing portfolio of exciting targets, including ENV-105, KROS-201, KROS-102 and ENV-205. We remain committed to seeing these therapeutics through the clinical system alongside our partners utilizing non-dilutive clinical funding as much as possible. Other highlights from this quarter include: Kairos Pharma Presented at the 3rd Annual DealFlow Discovery Conference Our CSO Dr. Neil Bhowmick Interviewed with the RedChip Small Stocks Big Money Show Kairos Pharma participated in The Scientist's two-day symposium on Emerging Therapeutic Strategies in Oncology As Kairos continues to showcase the potential of our drug candidates, we anticipate the following key milestones for the rest of 2026, including: The initiation of a Phase 1 study with CL-741 targeting EGFR-mutated lung cancer Continued execution in the second phase of our randomized clinical trial of ENV-105 in prostate cancer, with more trial sites expected to be announced before the end of the year Continued execution of our Phase 1 clinical trial of ENV-105 in non-small cell l...

View stock analysis, news, and events for Kairos Pharma, Ltd.